FGK Clinical Researchsp. z o.o.
Research and experimental development in natural sciences and engineering
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2010-10-29
Share capital
8,000.00 PLN
Registered address
ul. Hoża 55/45, 00-681 Warszawa, Poland
Electronic delivery address
AE:PL-76897-77703-DTCHT-19
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $1,283 |
Filing timeliness
Financial statements were filed on time, on average 34 days early.
- 202521/05/2026
- 202414/07/2025
- 202325/06/2024
- 202214/07/2023
- 202101/06/2022
- 202023/07/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Industry · Research and experimental development in natural sciences and engineering103 / 278
Top 37%
Results vs industry
Revenue
This companyUSD 441.16kMedianUSD 152.44kAverageUSD 4.84m
Net profit
This companyUSD 34.91kMedianUSD -258.82AverageUSD 315.06k
Operating costs
This companyUSD 394.49kMedianUSD 187.35kAverageUSD 4.65m
Assets
This companyUSD 160.08kMedianUSD 275.13kAverageUSD 8.44m
Industry
Authorized Representatives
Agnieszka Maria Ptaszyńskaage 49 – Attorney-in-fact (sole)
Heiko Debus – Attorney-in-fact (sole)
Martin Krauß – President of the Management Board
Ursula Türcke – Management Board Member
Manner of representation
Each member of the management board is authorized to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Fgk Clinical Research Gmbh | 160 | $2,160.99 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2011-05-25.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 18, 2020 | Other crisis aid | $5,900$5,900 | Prezydent Miasta Stołecznego Warszawy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Oncotransfersp. z o.o. | $704,767.72 | oncotransfer.pib-nio.pl | ||
| Smart FluidS.A. | $681,963.98 | smartfluid.pl | ||
| Lymelab Pharma sp. z o.o.sp. k. | $424,756.39 | lymelabpharma.com | ||
| Oasis DiagnosticsS.A. | $282,613.94 | oasis-diagnostics.com | ||
| NanosanguisS.A. | $192,701.50 | nanosanguis.com | ||
| Codeit4us Rndsp. z o.o. | $152,435.96 | codeit4us.com | ||
| VB IdeaP.S.A. | $44,631.63 | vbidea.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com | ||
| Nanostalsp. z o.o. | $8,607.48 | nanostal.com |
Change history
FAQ
The main business activity of FGK Clinical Research focuses on research and experimental development in natural sciences and engineering.
The company was registered in the Polish National Court Register (KRS) on October 29, 2010.
The headquarters is located at: ul. Hoża 55, 00-681 Warszawa.
The share capital of the company is PLN 8,000 (approx. $2,161).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of $441,162 in 2025, which is an increase of 25.3% compared to 2024.
Yes, in 2025 the company achieved a net profit of $34,914.
The largest operating cost category falls under employee remuneration. This category amounted to $195,005 in 2025, representing 49% of all operating expenses.
Last updated: 2026-10-07
